Additional file 3: of Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia Guillermo Garcia-Manero Antonio Almeida Aristoteles Giagounidis Uwe Platzbecker Regina Garcia Maria Voso Stephen Larsen David Valcarcel Lewis Silverman Barry Skikne Valeria Santini 10.6084/m9.figshare.c.3610133_D2.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_3_of_Design_and_rationale_of_the_QUAZAR_Lower-Risk_MDS_AZA-MDS-003_trial_a_randomized_phase_3_study_of_CC-486_oral_azacitidine_plus_best_supportive_care_vs_placebo_plus_best_supportive_care_in_patients_with_IPSS_lower-risk_myelodysplastic_/4359761 Supplementary Appendix for Protocol AZA-MDS-003, Amendment number 2.0, (08 Oct 2015). (DOCX 39 kb) 2016-05-03 05:00:00 Myelodysplastic syndromes MDS IPSS lower risk CC-486 Azacitidine Red blood cell transfusion dependence Anemia Thrombocytopenia